arrow
O

Oronzo Brunetti

irccs - istituto tumori giovanni paolo ii
H指数:42
被引数:4,775

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Disitamab vedotin in urothelial carcinoma patients: a clinical trial perspective from ARON working group

替斯安单抗维多汀在尿路上皮癌患者中的应用:ARON工作组临床试验视角

2026-10-070
PRE
Nutritional status and survival outcomes in patients with cancer treated with immune checkpoint inhibitors: The ARON-MOUSEION-20 systematic review and meta-analysis

免疫检查点抑制剂治疗癌症患者的营养状况与生存结局:ARON-MOUSEION-20系统评价与Meta分析

2026-09-300
PRE
Integrated single cell RNA sequencing and flow cytometry analysis identifies elevated S100A6+and S100A8+myeloid subsets in pancreatic ductal adenocarcinoma

整合单细胞RNA测序和流式细胞术分析发现胰腺导管腺癌中S100A6+和S100A8+髓系亚群升高

2026-01-010
OAAI
Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2EV project

接受恩沃利单抗维多汀治疗的局部晚期或转移性尿路上皮癌患者的骨转移:ARON-2EV项目真实世界研究

2025-12-290
OAAI
Infusion-Related Reactions Among Cancer Patients Receiving Immune Checkpoint Inhibitors: The ARON-MOUSEION-013 Systematic Review and Meta-Analysis

免疫检查点抑制剂治疗癌症患者中的输注相关反应:ARON-MOUSEION-013系统评价与荟萃分析

2025-12-130
OA
Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: a secondary endpoint of the ARMANI phase 3 trial

帕克他赛和雷莫芦单抗序贯维持治疗在晚期胃肠癌中的患者报告结局:ARMANI III期试验的次要终点

2025-10-200
PRE
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset

预后免疫疗法评分(PIS)在经帕博利珠单抗治疗的晚期尿路上皮癌患者中的真实世界数据及ARON-2数据集验证

2025-09-060
PRE
Gender Medicine in Computed Tomography Radiomics Analysis to Predict Disease Progression in Liver Respectable Colorectal Cancer Patients

基于计算机断层扫描放射组学分析的性别医学在预测可切除结直肠癌患者疾病进展中的应用

2025-09-040
OAAI
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial
2025-04-080
OAAI
Adjuvant trastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: The TRINITY trial
2024-06-011
PRE
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study
2024-05-019
PRE